Analyst Sees Pent-Up Demand Impact On Astrana Health's Value-Based Care Model

Loading... Loading... Astrana serves over 10,000 providers and 1.0 million patients in value-based care arrangements. Thanks to its comprehensive delegation model, the Truist analyst was more confident in the company's ability to manage utilization and monitor trends. Truist upgraded the rating from Hold to Buy, with a price target of $50, up from$44. The analyst noted the multiple is supported by the company's attractive growth profile, relatively better visibility, strong profitability, and attractive ba ...